NASDAQ:AVGR - Nasdaq - US0537348775 - Common Stock - Currency: USD
0.474
-0.12 (-20.74%)
The current stock price of AVGR is 0.474 USD. In the past month the price decreased by -19.65%. In the past year, price decreased by -84.07%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.48 | 230.68B | ||
ISRG | INTUITIVE SURGICAL INC | 82.61 | 215.96B | ||
BSX | BOSTON SCIENTIFIC CORP | 41.89 | 154.97B | ||
SYK | STRYKER CORP | 31.69 | 147.27B | ||
MDT | MEDTRONIC PLC | 16.39 | 112.21B | ||
BDX | BECTON DICKINSON AND CO | 16.37 | 65.40B | ||
EW | EDWARDS LIFESCIENCES CORP | 28.51 | 44.06B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.54 | 42.14B | ||
IDXX | IDEXX LABORATORIES INC | 40.41 | 37.22B | ||
DXCM | DEXCOM INC | 53.64 | 34.57B | ||
RMD | RESMED INC | 26.38 | 34.25B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 17.22 | 23.47B |
Avinger, Inc. is a commercial-stage medical device company, which engages in the designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease. The company is headquartered in Redwood City, California and currently employs 68 full-time employees. The company went IPO on 2015-01-30. The firm designs, manufactures, and sells real-time, image-guided, minimally invasive catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). Its Lumivascular platform includes the Lightbox real-time imaging console, the Ocelot and Tigereye family of catheters, which are image-guided catheters designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO), and the Pantheris family of catheters, its image-guided atherectomy family of catheters designed to allow physicians to remove arterial plaque in PAD patients. Its Pantheris is a single-use product and provides physicians with the ability to see a cross-sectional view of the peripheral artery to guide the removal of blockages throughout the procedure. The company has also developed a line extension of its Pantheris image-guided atherectomy platform, Pantheris Small Vessel (SV).
AVINGER INC
400 Chesapeake Dr
Redwood City CALIFORNIA 94063 US
CEO: Jeffrey M. Soinski
Employees: 71
Company Website: https://avinger.com/
Investor Relations: http://investors.avinger.com/phoenix.zhtml?c=253894&p=irol-IRHome
Phone: 16503632400
The current stock price of AVGR is 0.474 USD. The price decreased by -20.74% in the last trading session.
The exchange symbol of AVINGER INC is AVGR and it is listed on the Nasdaq exchange.
AVGR stock is listed on the Nasdaq exchange.
7 analysts have analysed AVGR and the average price target is 5.1 USD. This implies a price increase of 975.95% is expected in the next year compared to the current price of 0.474. Check the AVINGER INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
AVINGER INC (AVGR) has a market capitalization of 1.57M USD. This makes AVGR a Nano Cap stock.
AVINGER INC (AVGR) currently has 71 employees.
AVINGER INC (AVGR) has a resistance level at 0.91. Check the full technical report for a detailed analysis of AVGR support and resistance levels.
The Revenue of AVINGER INC (AVGR) is expected to decline by -12.9% in the next year. Check the estimates tab for more information on the AVGR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AVGR does not pay a dividend.
AVINGER INC (AVGR) will report earnings on 2025-03-18, after the market close.
AVINGER INC (AVGR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.03).
The outstanding short interest for AVINGER INC (AVGR) is 4.33% of its float. Check the ownership tab for more information on the AVGR short interest.
ChartMill assigns a fundamental rating of 2 / 10 to AVGR. The financial health of AVGR is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months AVGR reported a non-GAAP Earnings per Share(EPS) of -11.03. The EPS increased by 66.4% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -127.59% | ||
ROE | -447.82% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to AVGR. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -30.64% and a revenue growth -12.9% for AVGR